The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) drugs in development market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) by 16 companies/universities/institutes. The top development phase for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) is preclinical with seven drugs in that stage. The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline has 15 drugs in development by companies and one by universities/ institutes. Some of the companies in the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline products market are: RegenxBio, Generium and AngioChem.

The key targets in the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline products market include Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13).

The key mechanisms of action in the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline product include Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Activator with seven drugs in Phase III. The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline products include seven routes of administration with the top ROA being Intravenous and six key molecule types in the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline products market including Gene Therapy, and Recombinant Enzyme.

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) overview

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features including thickening of the lips, tongue, and nostrils, and delayed development. Treatment includes bone marrow transplantation, enzyme therapy, and gene therapy.

For a complete picture of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.